Evidence map›Paper›PMID 25295731›Full record

ArticlePloS one2014

Acylation of Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability.

Sofie Trier, Lars Linderoth, Simon Bjerregaard, Thomas Lars Andresen, Ulrik Lytt Rahbek

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Lipid regulation of the glucagon receptor family.The Journal of endocrinology · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. PeptideFrontiers in nutrition · 2022
    Article
  8. Article
  9. Article
  10. A review of lipidation in the development of advanced protein and peptide therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sofie TrierDept. of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Kgs. Lyngby, Denmark; Diabetes Research Unit, Novo Nordisk, Maaloev, Denmark.
Lars LinderothDiabetes Research Unit, Novo Nordisk, Maaloev, Denmark.
Simon BjerregaardDiabetes Research Unit, Novo Nordisk, Maaloev, Denmark.
Thomas Lars AndresenDept. of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Kgs. Lyngby, Denmark.
Ulrik Lytt RahbekDiabetes Research Unit, Novo Nordisk, Maaloev, Denmark.
Novo Nordisk (Denmark) · DKTechnical University of Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcylation of peptide drugs with fatty acid chains has proven beneficial for prolonging systemic circulation as well as increasing enzymatic stability without disrupting biological potency. Acylation has furthermore been shown to increase interactions with the lipid membranes of mammalian cells. The extent to which such interactions hinder or benefit delivery of acylated peptide drugs across cellular barriers such as the intestinal epithelia is currently unknown. The present study investigates the effect of acylating peptide drugs from a drug delivery perspective. PURPOSE: We hypothesize that the membrane interaction is an important parameter for intestinal translocation, which may be used to optimize the acylation chain length for intestinal permeation. This work aims to characterize acylated analogues of the intestinotrophic Glucagon-like peptide-2 by systematically increasing acyl chain length, in order to elucidate its influence on membrane interaction and intestinal cell translocation in vitro.

resultsPeptide self-association and binding to both model lipid and cell membranes was found to increase gradually with acyl chain length, whereas translocation across Caco-2 cells depended non-linearly on chain length. Short and medium acyl chains increased translocation compared to the native peptide, but long chain acylation displayed no improvement in translocation. Co-administration of a paracellular absorption enhancer was found to increase translocation irrespective of acyl chain length, whereas a transcellular enhancer displayed increased synergy with the long chain acylation.

conclusionsThese results show that membrane interactions play a prominent role during intestinal translocation of an acylated peptide. Acylation benefits permeation for shorter and medium chains due to increased membrane interactions, however, for longer chains insertion in the membrane becomes dominant and hinders translocation, i.e. the peptides get 'stuck' in the cell membrane. Applying a transcellular absorption enhancer increases the dynamics of membrane insertion and detachment by fluidizing the membrane, thus facilitating its effects primarily on membrane associated peptides.

Indexed as

AcylationAmino Acid SequenceCaco-2 CellsCell MembraneGlucagon-Like Peptide 2Glucagon-Like Peptide-2 ReceptorHumansIntestinal AbsorptionIntestinal MucosaIntestinesMolecular Sequence DataPermeabilityProtein BindingProtein TransportReceptors, GlucagonGlucagon-Like Peptide 2Glucagon-Like Peptide-2 ReceptorReceptors, Glucagon

Identifiers

PMID25295731
PMCPMC4190408
OpenAlexW2006036698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.